Prevalence of Hyperuricemia and Associated Factors Among Type 2 Diabetic Patients in Jordan

Abstract

Background: Previous studies showed variable estimate of the prevalence of hyperuricemia in patients with type 2 diabetes mellitus (T2DM). The prevalence of hyperuricemia and associated risk factors in Jordanian patients with T2DM is largely unknown. Therefore, this study aimed to determine the prevalence of hyperuricemia and its associated factors in Jordanian patients with T2DM. Methods: A cross-sectional study was conducted on 655 patients with T2DM. A structured questionnaire was used to collect socio-demographic data. In addition, records of the study subjects were reviewed to obtain other clinical data. Weight, height, and waist circumference were measured, and body mass index was calculated. Lipid profile, serum uric acid and glycated haemoglobin were analysed. The study was conducted in accordance with the Declaration of Helsinki. An informed written consent was obtained from each participant. The confidentiality of the information was assured and only used for scientific purposes. Results: Overall, the prevalence of hyperuricemia was 28.1%. Female gender (OR: 2.37; 95%, CI: 1.63–3.45), intake of angiotensin-converting enzyme (ACE) and angiotensin-II receptor blockers (ARBs) (OR: 1.68; 95%, CI: 1.12–2.50), intake of β-blockers (OR: 2.20; 95%, CI: 1.51–3.22), increased waist circumference (OR: 3.17; 95%, CI: 1.39–7.22) and family history of hyperuricemia (OR: 2.56; 95%, CI: 1.57–4.16) were associated with increased odds of hyperuricemia. Conclusion: Hyperuricemia was high among type 2 diabetic patients, and screening test will be useful for those patients.